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ABSTRACT
Objectives: International guidelines recommend
thrombosis prophylaxis after total hip arthroplasty (THA)
and total knee arthroplasty (TKA) for up to 35 days.
However, previous studies often have hospital stays
(length of stay; LOS) of 8–12 days and not considering
early mobilisation, which may reduce incidence of venous
thromboembolic events (VTE). We investigated the
incidence of any symptomatic thromboembolic events
(TEEs) with only in-hospital prophylaxis if LOS ≤5 days
after fast-track THA and TKA.
Design: A prospective descriptive multicentre cohort
study in fast-track THA and TKA from February 2010 to
December 2011, with complete 90-day follow-up through
the Danish National Patient Registry and patient files.
Setting: 6 Danish high-volume centres with a similar
standardised fast-track setup, including spinal
anaesthesia, opioid-sparing analgesia, early mobilisation,
functional discharge criteria and discharge to own home.
Participants: 4924 consecutive unselected unilateral
primary THA and TKAs in patients ≥18 years with no
preoperative use of continuous ‘potent’ anticoagulative
therapy (vitamin K antagonists).
Exposure: Prophylaxis with low-molecular-weight
heparin or factor Xa-inhibitors only during hospitalisation
when LOS ≤5 days.
Outcomes: Incidence of symptomatic TEE-related, VTE-
related and VTE-related mortality ≤90 days
postoperatively.
Results: LOS≤5 days and thromboprophylaxis only
during hospitalisation occurred in 4659 procedures
(94.6% of total). Median LOS and prophylaxis duration
was 2 days (IQR 2–3) with 0.84% (95% CI 0.62% to
1.15%) TEE and 0.41% (0.26% to 0.64%) VTE during
90-day follow-up. VTE consisted of five pulmonary
embolisms (0.11% (0.05% to 0.25%)) and 14 deep
venous thrombosis (0.30% (0.18% to 0.50%)). There
were four (0.09% (0.04% to 0.23%)) surgery-related
deaths, of which 1 (0.02% (0.00% to 0.12%)) was due to
pulmonary embolism, and 6 (0.13% (0.06% to 0.28%))
deaths of unknown causes after discharge.
Conclusions: The low incidence of TEE and VTE
suggests that in-hospital prophylaxis only, is safe in fast-
track THA and TKA patients with LOS of ≤5 days.
Guidelines on thromboprophylaxis may need
reconsideration in fast-track elective surgery.
Trial Registration: ClinicalTrials.gov: NCT01557725
INTRODUCTION
Venous thromboembolic events (VTE) such as
deep venous thrombosis (DVT) and pulmonary
embolism (PE) are well-documented risks in
hospitalised patients.1 Surgery presents an inde-
pendent risk factor for such events, due to both
the surgical trauma and postoperative immobil-
isation. Consequently, guidelines for post-
operative thromboprophylaxis have been
developed in both general and orthopaedic
surgery.2–4 However, the type and duration of
prophylaxis following elective surgery is debat-
able.5–7 For example, the American College of
Chest Physicians (ACCP) recommends either
mechanical prophylaxis using intermittent
pneumatic compressive devices (IPCD;
grade 1C), or pharmacological prophylaxis
(grade 1B), for up to 35 days (grade 2B) after
total hip (THA) and knee arthroplasty (TKA),2
whereas the American Academy of Orthopedic
Surgeons ﬁnd the evidence inconclusive and
decide the duration of thromboprophylaxis on
an individual basis.8 Much of the evidence
regarding the duration of thromboprophylaxis
after orthopaedic surgery has originated from
large randomised clinical trials (RCTs) in THA
and TKA with prophylaxis of 10–35 days,9–13
and these studies also contribute to guidelines
in general surgery.3 However, the pathophysio-
logical mechanisms of thrombosis have not
been addressed in RCTs, which often have long
length of stay (LOS) and lack focus on early
Strengths and limitations of this study
▪ A prospective multicentre trial in a large cohort
of consecutive unselected patients, with a stan-
dardised perioperative fast-track setup.
▪ Complete 90-day follow-up through the Danish
National Patient Registry and patient files.
▪ Registration of thromboembolic event (TEE) was
based on review of patient files, any TEE not
mentioned in these would not have been
registered.
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mobilisation, despite the fact that early mobilisation per se
may reduce the need for thromboprophylaxis.14
Fast-track surgery has been developed to improve recov-
ery by using evidence-based care principles with multi-
modal opioid-sparing analgesia, reduction of the surgical
stress-response, optimised ﬂuid treatment, adjustment of
the use of drains and catheters and early mobilisation.
These efforts have resulted in improved outcome following
various procedures such as colonic surgery and gynaeco-
logical procedures15 and major joint arthroplasty.16 It has
been suggested that reassessment of thromboembolic risk
in elective surgery is needed due to a few incidences of
VTE5 17; preliminary data have supported that fast-track
THA and TKA may decrease the risk of VTE and thereby
the need for prolonged prophylaxis.6 18 Consequently, we
designed a large prospective cohort study in unselected
consecutive patients having fast-track THA or TKA, with
thromboprophylaxis only during hospitalisation when the
LOS was ≤5 days. We hypothesised that there would be no
increase in symptomatic thromboembolic events (TEE)
and VTE with prophylaxis only during hospitalisation com-
pared with previous data with prophylaxis of 10–35 days.
METHODS
We investigated consecutive unselected primary elective
unilateral THA and TKA between 1 February 2010 and 1
December 2011 in patients ≥18 years with a Danish social
security number and no prescriptions on ‘potent’ anti-
coagulant therapy (ie, vitamin K antagonists, dabigatran,
rivaroxaban) ≤6 months preoperatively. Procedures in
patients with more than one THA or TKA during the study
period were excluded if <45 days between operations.
Five departments participated throughout the study
period, with a sixth department pausing between March
2010 and April 2011. All departments had a known mean
LOS of about 3–4 days, with a similar fast-track setup
including mobilisation on the day of surgery, identical
functional discharge criteria and discharge to own
home.19 Patients with the preoperative use of platelet inhi-
bitors (acetylsalicylic acid, clopidogrel, dipyridamole, etc)
ceased treatment 3–5 days prior to admission and
resumed treatment the day after surgery. All patients com-
pleted a preoperative questionnaire on characteristics and
comorbidity which was then entered into the Lundbeck
Foundation Centre Database (LCDB20; see online supple-
mentary appendix 1). Thromboprophylaxis was only given
during hospitalisation in patients with LOS of ≤5 days. If
the LOS was >5 days, prophylaxis was prescribed by the
attending surgeon according to local guidelines. The ﬁrst
dose of prophylaxis was given 6–8 h after surgery and con-
sisted of either rivaroxaban (Xarelto, Bayer Pharma,
Berlin, Germany) 10 mg/day, enoxaparin (Klexane,
Sanoﬁ-Aventis, Paris, France) 4000 IU/day, dalteparin
(Fragmin, Pﬁzer Health Care, New York, USA) 5000 IU/
day or fondaparinux (Arixtra, GlaxoSmithKline, London,
UK) 2.5 mg/day. No departments used IPCD. An interim
analysis and a random-sample audit on treatment and
data completion were conducted and approved by the
steering committee in 2011 (see online supplementary
appendix 2).
Preoperative data were cross-referenced with the Danish
National Patient Registry (DNPR) regarding LOS and
90-day readmissions (including emergency room contacts,
but excluding outpatient visits as clinical practice on treat-
ment of TEE in Denmark includes an initial admission to
hospital21). LOS was deﬁned as the number of post-
operative nights in the hospital (including transferal to
other departments) till discharge to the patients’ own
home. The DNPR registers all hospitalisations (including
transferals, diagnoses and surgical procedures) at Danish
hospitals, allowing information on the LOS and readmis-
sions regardless of localisation. Reporting is mandatory for
receiving reimbursement ensuring completeness of data
of about 99.4%.22 23 To detect TEE during primary admis-
sion the complete medical records of patients with diagno-
sis codes related to TEE according to the International
Classiﬁcation of Diseases 10th revision, all transfers to
other wards and the discharge summary of any patients
with LOS ≥5 days were investigated. In case of readmission
≤90 days, discharge ﬁles and/or patient ﬁles were investi-
gated with regard to relation to surgery.20 The criteria for
TEE were predeﬁned as: DVT conﬁrmed by ultrasound;
PE conﬁrmed by spiral CT; ventilation-perfusion scintig-
raphy or pathological removal of embolus and myocardial
infarction (MI) with rise in biomarkers and ischaemic
symptoms; diagnostic ECG changes; and primary coronary
intervention or a coronary bypass graft. An ischaemic
stroke was deﬁned as a neurological symptom >24 h and a
positive CT scan, and a transient ischaemic attack was
deﬁned as a neurological symptom lasting less than 24 h
and no new changes on CT scan. Mortality was obtained
through the Central Ofﬁce of Civil Registration using
unique Danish social security numbers. The cause of
death was obtained from the patient ﬁles/autopsies. In
case of death outside the hospital with no autopsy, the
patient’s general practitioner was contacted regarding the
cause of death. Adjudication of discharge summaries and
patient ﬁles, apart from reasons for LOS ≥5 days and
death during admission, was blinded with regard to the
duration of thrombosis prophylaxis. Adjudication was
carried out by the ﬁrst author (CCJ), and in case of pos-
sible TEE, the ﬁrst author (CCJ) and senior author (HK)
adjudicated cases together.
All prescriptions on ‘potent’ anticoagulant therapy and
platelet inhibitors 6 months before and 3 months after
surgery were investigated using The Danish National
Database of Reimbursed Prescriptions (DNDRP). During
the study period all prescriptions on ‘potent’ anticoagu-
lant treatment received government reimbursements
securing 100% completeness of data.24 Patients without
prescriptions on anticoagulative therapy but answering
‘yes’ in the questionnaire were assumed to use platelet
inhibitors. In 21 procedures in patients with LOS ≤5 days
we found only postoperative prescriptions on ‘potent’
anticoagulative therapy. All hospital contacts of these
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patients were reviewed and, if insufﬁcient for determin-
ing the cause of the prescription, we contacted their
general practitioner. In two cases the prescription was
due to DVT found during outpatient visits without
regular hospital admission, while seven cases were due to
perioperative atrial-ﬂutter with treatment initiated
≥22 days after discharge. These were all retained in the
study cohort. The remaining 12 cases were due to speciﬁc
surgical considerations, discharge from other wards or
readmission with treatment despite unveriﬁed VTE.
These were considered protocol violations and included
in the unsuccessful early discharge cohort.
Outcomes
The primary outcome was the occurrence of symptomatic
TEE (DVT, PE, arterial embolism, MI, ischaemic stroke
or TCA) and VTE (DVT or PE) 90 days after THA/TKA
in patients with prophylaxis only during admission.
The secondary outcome was the occurrence of the
primary outcome in patients with thromboprophylaxis
after discharge. Bleeding events were protocolled as a
safety endpoint, but were hindered by incomplete regis-
tration. A separate analysis on patients not in the LCDB
was carried out to identify potential bias.
Statistics and power calculation
A prestudy power analysis using a two-tailed one sample
difference from constant test, found that 2838 patients
were needed to detect a 1% increase in TEE when assum-
ing a TEE rate of 3%, β: 82 and α: 0.05. Correspondingly,
2076 patients were needed to detect a 1% increase in
symptomatic VTE assuming a 90-day baseline risk of 2%.2
Data were tested for normality using q–q plots and histo-
grams. Comparisons of continuous data were made using
Mann-Whitney U test and t test and for categorical data
with χ2 test or Fisher’s exact test, as appropriate. Events
(incident cases) are reported as actual numbers and per-
centages with 95% CI using http://www.vassarstats.net/
prop1.html. All other analysis was carried out in SPSS V.20
(IBM Corporation, Armonk, New York, USA).
RESULTS
Total cohort
A total of 4924 procedures in 4718 patients were
included. The median LOS was 2 days (IQR 2–3), and
readmissions occurred after 400 (8.1%) of all procedures.
We found 50 (1.12%) TEE, of which 30 (0.58%) were
VTE. Symptomatic in-hospital TEE occurred after 7
(0.14% (0.07% to 0.29%)) procedures, of which 4
(0.08% (0.03% to 0.21%)) were VTE. All-cause mortality
was 0.42%, including one fatal PE (0.04%) and six deaths
of unknown causes (0.1%; table 2).
Successful early discharge cohort
Early discharge with LOS ≤5 days occurred in 4659
(94.6%) procedures in 4455 patients (ﬁgure 1). These
patients had a mean age of 66.8 years (SD 10.7) with a
median LOS and prophylaxis duration of 2 days (IQR 2–3;
table 1). There were 353 (7.6%) surgery-related readmis-
sions of which 2.9% were due to ‘surgical’ morbidity (hip
displacements, prosthesis infections, knee manipulation,
etc) and 4.7% were due to ‘medical’ morbidity, such as
anaemia, cardiac arrhythmia, pneumonia, unveriﬁed pros-
thesis infection and pain.
A total of 39 (0.84%) TEE were found within 90 days,
of which 24 (0.52%, 95% CI 0.35% to 0.77%) occurred
during the ﬁrst postoperative month. One patient was
readmitted twice due to ischaemic strokes on post-
operative days 8 and 46. According to the medical
records, the second stroke was cardiac in origin as the
patient was known to have an atrial ﬂutter, but treated
only with acetylsalicylic acid due to gastrointestinal
bleeding. There were 19 (0.41%) symptomatic VTE
(ﬁgures 2 and 3A), consisting of 5 (0.11%) PEs and 14
(0.30%) DVTs of which 9 were proximal (table 2).
Median time to VTE was 21 days (IQR 8–39), with 12
VTE ≤30 days postoperatively (30-day VTE rate 0.26%,
95% CI 0.15% to 0.45%).
There were 13 (0.28%) deaths during follow-up. Of
these three (0.06%) were unrelated to surgery (cancer
and gastric morbidity >45 days after surgery) and six
(0.13%) were of unknown causes outside hospital (post-
operative day: 19, 27, 36, 44, 48 and 85). Thus, four
(0.09%) deaths were conﬁrmed surgically related
(table 2), one due to an autopsy conﬁrmed PE on post-
operative day 41 and one due to intracerebral bleeding
on day 26. The remaining two deaths were due to para-
lytic ileus on postoperative day 36 and sepsis on post-
operative day 24.
Unsuccessful early discharge cohort: This cohort of 265
(5.4%) procedures in 263 patients (ﬁgure 1), was older
and had more comorbidity than the early discharge
cohort (table 1). The median LOS was 7 days (IQR 6–9)
with 47 (17.7%) surgically related readmissions (5.7%
‘surgical’ and 12% ‘medical’ morbidity). Of 11 (4.97%)
TEE with 7 (2.65%) VTE (table 2), 7 and 4, respectively,
occurred during index hospitalisation consequently
resulting in LOS >5 days. Of the four (1.51% (95% CI
0.59% to 3.82%)) TEE after discharge, one (0.38%
(0.07% to 2.11%)) was an ischaemic stroke and three
were VTE (1.13% (0.38% to 3.27%)), with two PEs
(0.75% (0.21% to 2.70%)) and one DVT (0.38% (0.07%
to 2.11%)). Median time to VTE was 3 days (IQR 2–53;
ﬁgure 3B). We found three (1.13%) surgically related
deaths, one death unrelated to surgery (paralytic ileus on
day 70 in a patient refusing treatment) and no
VTE-related deaths or deaths of unknown causes (0.00%
(0.00% to 1.43%)).
Patients not in LCDB (3.6%)
In these 194 (108 THA/86 TKA) procedures in 191
patients, the mean age was 68.5 years (SD 11.0) and 178
(91.8%) had LOS ≤5 days. In these 178 procedures
there was one (0.56% (0.10% to 3.11%)) readmission
due to an MI, no VTE and no deaths. No further
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analysis was carried out as no bias was apparent com-
pared to the study population.
DISCUSSION
In this prospective study in fast-track primary THAs and
TKAs, we found 90-day postoperative rates of symptom-
atic TEE and VTE of 0.84% and 0.41%, respectively, in
patients with LOS ≤5 days and in-hospital thrombopro-
phylaxis only. The patients receiving prophylaxis only
during index hospitalisation (median 2 days) contribu-
ted 94.6% of the total number of performed proce-
dures, as 5.4% had LOS >5 days and consequently
received longer prophylaxis. The study has several
strengths, such as a consecutive unselected population
including high-risk patients with various types of
comorbidity, a standardised perioperative fast-track setup
and complete detailed 90-day follow-up.
We used any TEE as primary endpoint in order not to
overlook a potential worsened outcome. Stroke and MI
have been included as safety endpoints in most RCTs,10–12
but are often neglected in reviews and database studies.25–27
We found no increase in the occurrence of ischaemic
stroke as compared with previous studies of in-hospital
stroke in THA28 and strokes ≤30 days in both TKA and
THA,29 despite our follow-up being 90 days and not relying
on diagnostic codes. Neither was there any apparent
increase in the occurrence of MI compared with a recent
study which found MI in 0.51% of THA and 0.21% of TKA
after 6 weeks.30 The numbers of symptomatic VTE were
lower or comparable to the RCTs with prophylaxis of 10–
35 days.10–13 However, LOS in these RCTs was 8–12 days
with unspeciﬁed discharge locations, whereas LOS after
94.6% of procedures in our study was ≤5 days until dis-
charge to own home. The long LOS in these studies may
include partial immobilisation, thereby increasing the risk
of VTE and consequently the need for thromboprophylaxis.
Correspondingly, a previous small-scale study in 247 TKA
found a decreased risk of DVT following mobilisation
within 24 h of surgery,14 and an earlier fast-track single-
centre study with prophylaxis only during admission in
1977 THA and TKAs with a mean LOS of about 3.5 days
found 0.86% symptomatic VTE within 90 days.18
Another main difference between our study and the
RCTs is that there was no preoperative selection of
patients, as the duration of prophylaxis depended only
on discharge within 5 days, regardless of comorbidity.
Thus, our results reﬂect ‘everyday patients’, whereas the
exclusion criteria in the RCTs may have reduced occur-
rences of TEE.8 31 The only excluded patients in our
study were those using preoperative ‘potent’ anticoagu-
lant therapy, since they obviously needed continuation
Figure 1 Flow chart of the study
population. THA, total hip
arthroplasty; TKA, total knee
arthroplasty.
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after discharge. Two Danish nationwide studies found
symptomatic VTE in >1% of THA and TKA despite pro-
longed prophylaxis, and that the incidence was
increasing across the study periods (1995–2007).26 32
The difference between these data and ours may be due
to the fast-track set-up including early mobilisation in
Table 1 Preoperative patient characteristics and prophylaxis duration
Characteristic
Early
discharge
N: 4659
‘Unsuccessful’
early discharge
N: 265 p Value Characteristic
Early
discharge
N: 4659
‘Unsuccessful’
early discharge
N: 265 p Value
Age (SD) (years) 66.8 (10.7) 73.0 (12.1) <0.001 BMI (SD) 28.4 (5.1) 27.9 (5.7) 0.110
<50 313 (6.7) 11 (4.2) <18.5 35 (0.8) 5 (1.9)
50–60 855 (18.4) 28 (10.6) 18.5–24.9 1186 (25.6) 79 (30.4)
61–65 779 (16.7) 19 (7.2) 25.0–29.9 1865 (40.2) 102 (39.2)
66–70 916 (19.7) 34 (12.8) 30.0–39.9 1426 (30.7) 63 (26.0)
71–75 807 (17.3) 47 (17.7) ≥40 126 (2.7) 11 (3.7)
76–80 585 (12.6) 50 (18.9) Missing 21 (0.5) 5 (1.9)
81–86 302 (6.5) 45 (17.0)
>86 102 (2.2) 31 (11.7)
Gender 0.002 Joint 0.961
Females 2654 (57.0) 177 (66.8) THA 2451 (52.6) 139 (52.5)
Males 2005 (43.0) 88 (33.2) TKA 2208 (47.4) 126 (47.5)
Use of compressive
stockings
<0.001 Diabetes 0.426
T1D 14 (0.3) 2 (0.7)
Yes 250 (5.5) 35 (13.7) T2D 505 (10.9) 30 (11.5)
No 4267 (94.5) 220 (86.3) None 4112 (88.8) 230 (87.8)
Missing 142 (3.0) 10 (3.8) Missing 28 (0.6) 3 (1.1)
Social situation <0.001 Hypertension <0.001
Living with others 3117 (66.9) 117 (44.2) Yes 2291 (49.5) 161 (61.2)
Living alone 1502 (32.2) 139 (52.5) No 2335 (50.5) 102 (38.8)
Nursing home, etc 40 (0.9) 9 (3.4) Missing 33 (0.7) 2 (0.8)
Use of walking aid 1078 (23.7) 142 (55.0) <0.001 Pharmacologically
treated PsD
<0.001
Yes 3469 (76.3) 116 (45.0) Yes 311 (6.7) 33 (12.6)
No 112 (2.4) 7 (2.6) No 4308 (93.3) 228 (87.4)
Missing Missing 40 (0.9) 4 (1.5)
Hypercholesterolaemia 0.044 Prior cerebral stroke <0.001
Yes 1289 (28.0) 89 (33.7)
No 3321 (72.0) 175 (66.3) Yes 250 (5.5) 29 (11.2)
Missing 49 (1.1) 1 (0.4) No 4336 (94.5) 229 (88.8)
Missing 73 (1.6) 7 (2.6)
Smoking 0.058 Prior VTE <0.001
Yes 703 (15.2) 51 (19.2) Yes 179 (3.9) 22 (8.5)
No 3908 (84.8) 209 (80.4) No 4401 (96.1.0) 261 (91.5)
Missing 48 (1.0) 5 (1.9) Missing 79 (1.7) 6 (2.3)
Alcohol >2 units daily 0.015 Relative with VTE 0.023
Yes 345 (7.5) 9 (3.4) Yes 507 (12.2) 16 (7.1)
No 4263 (91.5) 252 (96.6) No 3643 (87.8) 208 (92.9)
Missing 51 (1.1) 4 (1.5) Missing 509 (10.9) 41 (15.5)
Pharmacologically
treated PD
0.094 Anticoagulative
treatment
<0.001
Yes 333 (7.2) 26 (10.0) Platelet inhibitors 1284 (26.2) 120 (39.7)
No 4286 (92.8) 264 (90.0) None 3375 (68.9) 145 (48.0)
Missing 44 (0.9) 5 (1.9) Missing 0 (0) 0 (0)
Pharmacologically
treated CD
0.005 Duration of
prophylaxis
Yes 418 (9.1) 37 (14.4) Mean (SD) 2.5 (0.91) N/A
No 4175 (90.9) 220 (85.6) Median (IQR) 2 (2–3) N/A
Missing 66 (1.4) 8 (3.0)
Data reported as n (%) for counts and mean for continuous variables unless otherwise specified.
BMI, body mass index; CD, cardiac disease; LOS, length of hospital stay; N, procedures; N/A, not available; PD, pulmonary disease;
PsD, psychiatric disease; T1D, type 1 diabetes; T2D, type 2 diabetes; THA, total hip arthroplasty; TKA, total knee arthroplasty; VTE, venous
thromboembolic event.
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our study, and since LOS in Denmark was about 11 days
in year 2000.33
The occurrence of in-hospital TEE in the total 4924
procedures in the LCDB was low (0.14%), and particu-
larly the incidence of symptomatic in-hospital VTE
(<0.10%) was lower than the 0.5% in THA and 1% in
TKA found in a recent review.25 Although the timing of
VTE, with the majority occurring within the ﬁrst month
is consistent with previous studies,2 34 we believe that the
low incidence questions the beneﬁts of prolonged
prophylaxis in all patients after fast-track THA and TKA.
Further studies are needed to identify whether certain
patient subgroups may beneﬁt from more extensive or
intensive prophylaxis, and how to avoid in-hospital TEE
while patients are receiving recommended treatment.
However, due to the few events the numbers of patients
needed for such studies pose major challenges.
Finally, we report both conﬁrmed VTE-related death
and a ‘worst case’ scenario, with death of unknown
causes being considered VTE-related, despite that cause
of death after THA/TKA often is found unrelated to
VTE.35 Thus, we found only one veriﬁed fatal PE, and a
90-day all-cause mortality comparable to or lower than
previous studies.27 36–38
The ‘unsuccessful’ early discharge cohort was older
with more comorbidity and readmissions. This is not sur-
prising, as we have previously found an association with
LOS and readmissions after fast-track THA and TKA in
such patients.20 There were about 2% PEs in these
patients, but this is in accordance with comorbidities
such as cardiac disease or previous TEE, being asso-
ciated with cardiac and thromboembolic complications
after arthroplasty.27 Furthermore, complications per se
Figure 3 (A and B) Timing of
type of TEE in the early
discharge cohort (A) and the
‘unsuccessful’ early discharge
cohort (B). TEE, thromboembolic
event; VTE, venous
thromboembolic event. Dotted
line marks postoperative day 30.
Figure 2 Cumulated incidence of symptomatic venous
thromboembolic events.
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may lead to prolonged LOS and thereby longer prophy-
laxis. Thus, about 60% of TEE and VTE in this cohort
occurred during primary admission. However, it does
not argue against our conclusion that prophylaxis only
during admission is safe when LOS ≤5 days.
Our study has limitations, foremost regarding the
follow-up which was based on hospital contacts. However,
although the reliability of diagnostic codes for VTE in
DNPR may be low,39 the completion of data regarding
somatic admissions is close to 100%.22 39 Consequently, we
investigated all admissions through discharge summaries
and patient ﬁles instead of relying only on diagnostic codes,
as often carried out in large-scale cohort studies.26 32 40
Although TEE may have been left out of the discharge
summary, this seems unlikely, as they require treatment
after discharge. We also used the DNDRP to detect proce-
dures followed by a postoperative prescription of potent
anticoagulant therapy, thereby ensuring that any TEE diag-
nosed in outpatient clinics would be registered. The
DNDRP is ideally suited for this, as all prescriptions on oral
anticoagulants in Denmark receive reimbursement and are
therefore recorded. Regarding TEE during primary admis-
sion, ideally we should have investigated the discharge sum-
maries of every procedure with LOS ≤5 days. However, as
TEEs are serious complications they would require pro-
longed hospitalisation. Thus, LOS in all seven patients with
TEE during primary admission was >5 days (ﬁgure 3B).
The local guidelines for thrombosis prophylaxis in the
participating departments were 6–10 days after discharge
when LOS >5 days, and therefore it may be problematic that
we do not have exact data on the duration of prophylaxis for
the secondary cohort. However, this does not change the
conclusion—that prophylaxis only during admission is safe
in THA and TKA with LOS ≤5 days. It could also be argued
that our study should have been carried out as an RCT.
However we did not attempt to compare two types of treat-
ment. Instead, for complex medical situations detailed
cohort studies have been proposed as a viable, and some-
times preferable, alternative.41 42 In this context, a post hoc
analysis assuming a 2% baseline risk of symptomatic VTE
with extended LMWH prophylaxis of about 35 days2 found
the actual power of our study to be 99% due to the large
number of patients. Whether our cut-off of 5 days LOS is an
optimal way of deciding on duration of prophylaxis is uncer-
tain, but it seems unlikely that patients with a satisfactory fast-
track procedure would have a longer LOS.33 37 However, it is
worth noticing that >75% of procedures were followed by
LOS, and consequently thromboprophylaxis, for ≤3 days
and that about 95% of all procedures had LOS ≤5 days.
In conclusion, we found low rates of TEE and VTE after
primary elective fast-track THA and TKAwith thrombopro-
phylaxis only during hospitalisation in patients with LOS
≤5 days. These results support previous ﬁndings from
other types of surgery, suggesting that guidelines on post-
operative thromboprophylaxis need reconsideration in
modern elective surgical procedures.
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Rigshospitalet, Copenhagen University, Copenhagen, Denmark
Table 2 VTEs, all TEEs and mortality
Outcomes All procedures (n: 4924) Early discharge (n: 4659)
‘Unsuccessful’ early
discharge (n: 265)
PE 10 (0.21; (0.12 to 0.38)) 5 (0.11; (0.05 to 0.25)) 5 (1.99; (0.92 to 4.27))
Any DVT 16 (0.37; (0.24 to 0.58)) 14 (0.30; (0.18 to 0.50)) 2 (0.67; (0.18 to 2.38))
Proximal DVT 11 (0.23; (0.13 to 0.41)) 9 (0.19; (0.10 to 0.36)) 2 (0.67; (0.18 to 2.38))
Any VTE 30 (0.58; (0.41 to 0.83)) 19 (0.41; (0.26 to 0.64)) 7 (2.65; (1.35 to 5.14))
Any VTE (THA/TKA) 17/13 (0.62; (0.39 to 0.99))/
(0.53; (0.31 to 0.90))
15/4 (0.61; (0.37 to 1.00))/
(0.18; (0.07 to 0.46))
1/6 (0.65; (0.11 to 3.60))/
(4.70; (2.31 to 9.38))
Myocardial infarction 8 (0.17; (0.09 to 0.32)) 7 (0.15; (0.07 to 0.31)) 1 (0.33; (0.06 to 1.85))
Ischaemic stroke 8 (0.19; (0.10 to 0.35)) 6 (0.13; (0.06 to 0.28)) 2 (0.99; (0.34 to 2.87))
Transient ischaemic attack 7 (0.15; (0.08 to 0.30)) 7 (0.15; (0.07 to 0.31)) 0 (0.33; (0.06 to 1.85))
Arterial embolus 1 (0.04; (0.01 to 0.14)) 0 (0.00; (0.00 to 0.08)) 1 (0.66; (0.18 to 2.38))
Any TEE 50 (1.12; (0.87 to 1.44)) 39 (0.84; (0.62 to 1.15)) 11 (4.97; (3.04 to 8.04))
Any TEE (THA/TKA) 29/21 (1.17; (0.83 to 1.65))/
(1.05; (0.72 to 1.53))
27 /12 (1.10; (0.76 to 1.60))/
(0.54; (0.31 to 0.94))
2/9 (1.96; (0.67 to 5.60))/
(8.05; (4.66 to 13.54))
All-cause mortality 17 (0.42; (0.28 to 0.64)) 13 (0.28; (0.16 to 0.49)) 4 (1.99; (0.92 to 4.27))
Unrelated to surgery 4 (0.10; (0.04 to 0.23)) 3 (0.06; (0.01 to 0.20)) 1 (0.33; (0.06 to 1.85))
Surgically related mortality 7 (0.19; (0.10 to 0.35)) 4 (0.09; (0.04 to 0.23)) 3 (1.66; (0.71 to 3.82))
Death of unknown cause 6 (0.13; (0.06 to 0.27)) 6 (0.13; (0.06 to 0.28)) 0 (0.00; (0.00 to 1.26))
Fatal PE 1 (0.04; (0.01 to 0.14)) 1 (0.02; (0.00 to 0.12)) 0 (0.33; (0.06 to 1.85))
Fatal PE/death of unknown cause 7 (0.17; (0.09 to 0.32)) 7 (0.15; (0.07 to 0.31)) 0 (0.33; (0.06 to 1.85))
Any VTE or death of unknown cause 32 (0.71; (0.52 to 0.98)) 25 (0.54; (0.37 to 0.80)) 7 (2.65; (1.35 to 5.14))
Any TEE or death of unknown cause 56 (1.25; (0.98 to 1.59)) 45 (0.97; (0.73 to 1.29)) 11 (4.97; (3.04 to 8.04))
Data reported as counts n (%; (95% CI)).
DVT, deep venous thrombosis; PE, pulmonary embolism; TEE, thromboembolic events; THA, total hip arthroplasty; TKA, total knee
arthroplasty; VTE, venous thromboembolic events.
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